Protection of CDC25 phosphatases against oxidative stress in breast cancer cells: Evaluation of the implication of the thioredoxin system

References

• Veal EA, Day AM, Morgan BA. Hydrogen peroxide sensing and signaling. Mol Cell 2007;26:1–14.
   PubMed Web of Science ®Google Scholar
• Groeger G, Quiney C, Cotter TG. Hydrogen peroxide as a cell-survival signaling molecule. Antioxid Redox Signal 2009;11:2655–2671.
   PubMed Web of Science ®Google Scholar
• Burhans WC, Heintz NH. The cell cycle is a redox cycle: linking phase-specific targets to cell fate. Free Radic Biol Med 2009;47:1282–1293.
   PubMed Web of Science ®Google Scholar
• Rhee SG. Cell signaling. H2O2, a necessary evil for cell signaling. Science 2006;312:1882–1883.
   PubMed Web of Science ®Google Scholar
• Salmeen A, Barford D. Functions and mechanisms of redox regulation of cysteine-based phosphatases. Antioxid Redox Signal 2005;7:560–577.
   PubMed Web of Science ®Google Scholar
• Chiarugi, P. Survival or death: the redox paradox. Antioxid Redox Signal 2009;11:2651–2654.
   Google Scholar
• Paulsen CE, Carroll KS. Orchestrating redox signaling networks through regulatory cysteine switches. ACS Chem Biol 2010;5:47–62.
   PubMed Web of Science ®Google Scholar
• Lee, SR, Kwon KS, Kim SR, Rhee SG. Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J Biol Chem 1998;273:15366–15372.
   PubMed Web of Science ®Google Scholar
• Meng TC, Buckley DA, Galic S, Tiganis T, Tonks NK. Regulation of insulin signaling through reversible oxidation of the protein-tyrosine phosphatases TC45 and PTP1B. J Biol Chem 2004;279:37716–37725.
   PubMed Web of Science ®Google Scholar
• Chiarugi P, Pani G, Giannoni E, Taddei L, Colavitti R, Raugei G, . Reactive oxygen species as essential mediators of cell adhesion: the oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion. J Cell Biol 2003;161:933–944.
   PubMed Web of Science ®Google Scholar
• Yu CX, Li S, Whorton AR. Redox regulation of PTEN by S-nitrosothiols. Mol Pharmacol 2005;68:847 – 854.
   PubMed Web of Science ®Google Scholar
• Cho SH, Lee CH, Ahn Y, Kim H, Ahn CY, Yang KS, Lee SR. Redox regulation of PTEN and protein tyrosine phosphatases in H(2)O(2) mediated cell signaling. FEBS Lett 2004;560:7–13.
   PubMed Web of Science ®Google Scholar
• Chiarugi P, Fiaschi T, Taddei ML, Talini D, Giannoni E, Raugei G, Ramponi G. Two vicinal cysteines confer a peculiar redox regulation to low molecular weight protein tyrosine phosphatase in response to platelet-derived growth factor receptor stimulation. J Biol Chem 2001;276: 33478–33487.
   PubMed Web of Science ®Google Scholar
• Caselli A, Marzocchini R, Camici G, Manao G, Moneti G, Pieraccini G, Ramponi G. The inactivation mechanism of low molecular weight phosphotyrosine-protein phosphatase by H2O2. J Biol Chem 1998;273:32554–32560.
   PubMed Web of Science ®Google Scholar
• Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 2002;9:387–399.
   PubMed Web of Science ®Google Scholar
• Chen CY, Willard D, Rudolph J. Redox regulation of SH2-domain-containing protein tyrosine phosphatases by two backdoor cysteines. Biochemistry 2009;48: 1399–1409.
   PubMed Web of Science ®Google Scholar
• Sun JP, Wang WQ, Yang H, Liu S, Liang F, Fedorov AA, Almo SC, Zhang ZY. Structure and biochemical properties of PRL-1, a phosphatase implicated in cell growth, differentiation, and tumor invasion. Biochemistry 2005;44: 12009–12021.
   Google Scholar
• Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007;7:495–507.
   PubMed Web of Science ®Google Scholar
• Aressy B, Ducommun B. Cell cycle control by the CDC25 phosphatases. Anticancer Agents Med Chem 2008;8: 818–824.
   PubMed Web of Science ®Google Scholar
• Rudolph J. Redox regulation of the Cdc25 phosphatases. Antioxid Redox Signal 2005;7:761–767.
   Google Scholar
• Sohn J, Rudolph J. Catalytic and chemical competence of regulation of cdc25 phosphatase by oxidation/reduction. Biochemistry 2003;42:10060–10070.
   PubMed Web of Science ®Google Scholar
• Holmgren A, Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun 2010;396: 120–124.
   PubMed Web of Science ®Google Scholar
• Arner ES. Focus on mammalian thioredoxin reductases—important selenoproteins with versatile functions. Biochim Biophys Acta 2009;1790:495–526.
   PubMed Web of Science ®Google Scholar
• Brigelius-Flohe R, Flohe L. Basic principles and emerging concepts in the redox control of transcription factors. Antioxid Redox Signal 2011;15:2335–2381.
   PubMed Web of Science ®Google Scholar
• Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J, Nikaido T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 1999;274: 35809–35815.
   PubMed Web of Science ®Google Scholar
• Hansen JM, Watson WH, Jones DP. Compartmentation of Nrf-2 redox control: regulation of cytoplasmic activation by glutathione and DNA binding by thioredoxin-1. Toxicol Sci 2004;82:308–317.
   PubMed Web of Science ®Google Scholar
• Biaglow JE, Miller RA. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther 2005;4:6–13.
   PubMed Web of Science ®Google Scholar
• Lillig CH, Holmgren A. Thioredoxin and related molecules—from biology to health and disease. Antioxid Redox Signal 2007;9:25–47.
   PubMed Web of Science ®Google Scholar
• Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009;8:579–591.
   PubMed Web of Science ®Google Scholar
• Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006;10: 175–176.
   PubMed Web of Science ®Google Scholar
• Wondrak GT. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 2009;11:3013–3069.
   PubMed Web of Science ®Google Scholar
• Brault L, Denance M, Banaszak E, El Maadidi S, Battaglia E, Bagrel D, Samadi M. Synthesis and biological evaluation of dialkylsubstituted maleic anhydrides as novel inhibitors of Cdc25 dual specificity phosphatases. Eur J Med Chem 2007;42:243–247.
   PubMed Web of Science ®Google Scholar
• Ross DD, Joneckis CC, Ordonez JV, Sisk AM, Wu RK, Hamburger AWNRE, Nora RE. Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number. Cancer Res 1989;49:3776–3782.
   PubMed Web of Science ®Google Scholar
• Holmgren A. Bovine thioredoxin system. Purification of thioredoxin reductase from calf liver and thymus and studies of its function in disulfide reduction. J Biol Chem 1977;252:4600–4606.
   PubMed Web of Science ®Google Scholar
• Arner ES, Bjornstedt M, Holmgren A. 1-Chloro-2,4-dinitrobenzene is an irreversible inhibitor of human thioredoxin reductase. Loss of thioredoxin disulfide reductase activity is accompanied by a large increase in NADPH oxidase activity. J Biol Chem 1995;270:3479–3482.
   Google Scholar
• Rhee SG, Chang TS, Jeong W, Kang D. Methods for detection and measurement of hydrogen peroxide inside and outside of cells. Mol Cells 2010;29:539–549.
   PubMed Web of Science ®Google Scholar
• Watson WH, Pohl J, Montfort WR, Stuchlik O, Reed MS, Powis G, Jones DP. Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. J Biol Chem 2003;278:33408–33415.
   PubMed Web of Science ®Google Scholar
• Cox AG, Pullar JM, Hughes G, Ledgerwood EC, Hampton MB. Oxidation of mitochondrial peroxiredoxin 3 during the initiation of receptor-mediated apoptosis. Free Radic Biol Med 2008;44:1001–1009.
   Google Scholar
• Lenton KJ, Therriault H, Wagner JR. Analysis of glutathione and glutathione disulfide in whole cells and mitochondria by postcolumn derivatization high-performance liquid chromatography with ortho-phthalaldehyde. Anal Biochem 1999;274:125–130.
   PubMedGoogle Scholar
• Lacombe F, Belloc F. Flow cytometry study of cell cycle, apoptosis and drug resistance in acute leukemia. Hematol Cell Ther 1996;38:495–504.
   PubMedGoogle Scholar
• Viry E, Anwar A, Kirsch G, Jacob C, Diederich M, Bagrel D. Antiproliferative effect of natural tetrasulfides in human breast cancer cells is mediated through the inhibition of the cell division cycle 25 phosphatases. Int J Oncol 2011;38: 1103–11011.
   PubMed Web of Science ®Google Scholar
• Ou TT, Wang CJ, Lee YS, Wu CH, Lee HJ. Gallic acid induces G2/M phase cell cycle arrest via regulating 14 - 3-3beta release from Cdc25C and Chk2 activation in human bladder transitional carcinoma cells. Mol Nutr Food Res 2010;54:1781–1790.
   PubMed Web of Science ®Google Scholar
• Jin Y, Zou X, Feng X. 3,3′-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells. Anticancer Drugs 2010;21:814–822.
   Google Scholar
• Omata Y, Folan M, Shaw M, Messer RL, Lockwood PE, Hobbs D, . Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1). Toxicol In Vitro 2006;20:882–890.
   Google Scholar
• Gromer S, Arscott LD, Jr Williams CH, Schirmer RH, Becker K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 1998;273: 20096–20101.
   PubMed Web of Science ®Google Scholar
• Rigobello MP, Scutari G, Folda A, Bindoli A. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c. Biochem Pharmacol 2004;67: 689–696.
   PubMed Web of Science ®Google Scholar
• Myers CR, Myers JM. The effects of acrolein on peroxiredoxins, thioredoxins, and thioredoxin reductase in human bronchial epithelial cells. Toxicology 2009;257: 95–104.
   Google Scholar
• Yang X, Wu X, Choi YE, Kern JC, Kehrer JP. Effect of acrolein and glutathione depleting agents on thioredoxin. Toxicology 2004;204:209–218.
   PubMedGoogle Scholar
• Szadkowski A, Myers CR. Acrolein oxidizes the cytosolic and mitochondrial thioredoxins in human endothelial cells. Toxicology 2008;243:164–176.
   PubMed Web of Science ®Google Scholar
• Park YS, Misonou Y, Fujiwara N, Takahashi M, Miyamoto Y, Koh YH, Suzuki K, Taniguchi N. Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2005;327:1058–1065.
   PubMed Web of Science ®Google Scholar
• Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 2003;28:32–40.
   PubMed Web of Science ®Google Scholar
• Mah LJ, El-Osta A, Karagiannis TC. GammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010;24:679–686.
   PubMed Web of Science ®Google Scholar
• Landriscina M, Maddalena F, Laudiero G, Esposito F. Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxid Redox Signal 2009;11:2701–2716.
   PubMed Web of Science ®Google Scholar
• Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 2007;42:872–881.
   PubMed Web of Science ®Google Scholar
• Kim IS, Jin JY, Lee IH, Park SJ. Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br J Pharmacol 2004;142:749–755.
   Google Scholar
• Rigobello MP, Folda A, Dani B, Menabo R, Scutari G, Bindoli A. Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T cells. Eur J Pharmacol 2008;582:26–34.
   PubMed Web of Science ®Google Scholar
• Casini A, Hartinger C, Gabbiani C, Mini E, Dyson PJ, Keppler BK, Messori L. Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action. J Inorg Biochem 2008;102:564–575.
   PubMed Web of Science ®Google Scholar
• Cox AG, Brown KK, Arner ES, Hampton MB. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol 2008;76: 1097–1109.
   PubMed Web of Science ®Google Scholar
• Ludeman SM. The chemistry of the metabolites of cyclophosphamide. Curr Pharm Des 1999;5:627–643.
   PubMed Web of Science ®Google Scholar
• Prast-Nielsen S, Cebula M, Pader I, Arner ES. Noble metal targeting of thioredoxin reductase—covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin. Free Radic Biol Med 2010;49:1765–1778.
   Google Scholar
• Watson WH, Heilman JM, Hughes LL, Spielberger JC. Thioredoxin reductase-1 knock down does not result in thioredoxin-1 oxidation. Biochem Biophys Res Commun 2008;368:832–836.
   PubMedGoogle Scholar
• Rigobello MP, Gandin V, Folda A, Rundlof AK, Fernandes AP, Bindoli A, Marzano C, Bjornstedt M. Treatment of human cancer cells with selenite or tellurite in combination with auranofin enhances cell death due to redox shift. Free Radic Biol Med 2009;47:710–721.
   PubMed Web of Science ®Google Scholar
• Brown KK, Cox AG, Hampton MB. Mitochondrial respiratory chain involvement in peroxiredoxin 3 oxidation by phenethyl isothiocyanate and auranofin. FEBS Lett 2010;584: 1257–1262.
   Google Scholar
• Go YM, Halvey PJ, Hansen JM, Reed M, Pohl J, Jones DP. Reactive aldehyde modification of thioredoxin-1 activates early steps of inflammation and cell adhesion. Am J Pathol 2007;171:1670–1681.
   PubMed Web of Science ®Google Scholar
• Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 2007;1775: 92–102.
   PubMed Web of Science ®Google Scholar
• Chua PJ, Yip GW, Bay BH. Cell cycle arrest induced by hydrogen peroxide is associated with modulation of oxidative stress related genes in breast cancer cells. Exp Biol Med (Maywood) 2009;234:1086–1094.
   PubMed Web of Science ®Google Scholar
• Barnouin K, Dubuisson ML, Child ES, Fernandez de Mattos S, Glassford J, Medema RH, Mann DJ, Lam EW. H2O2 induces a transient multi-phase cell cycle arrest in mouse fibroblasts through modulating cyclin D and p21Cip1 expression. J Biol Chem 2002;277:13761–13770.
   PubMed Web of Science ®Google Scholar
• Natsuyama S, Noda Y, Yamashita M, Nagahama Y, Mori T. Superoxide dismutase and thioredoxin restore defective p34cdc2 kinase activation in mouse two-cell block. Biochim Biophys Acta 1993;1176:90–94.
   PubMed Web of Science ®Google Scholar
• Vogt A, Tamura K, Watson S, Lazo JS. Antitumor imidazolyl disulfide IV-2 causes irreversible G(2)/M cell cycle arrest without hyperphosphorylation of cyclin-dependent kinase Cdk1. J Pharmacol Exp Ther 2000;294: 1070–1075.
   PubMed Web of Science ®Google Scholar
• Neumann CA, Cao J, Manevich Y. Peroxiredoxin 1 and its role in cell signaling. Cell Cycle 2009;8:4072–4078.
   PubMed Web of Science ®Google Scholar
• Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, . Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. Embo J 2009;28:1505–1517.
   PubMed Web of Science ®Google Scholar
• Lowther WT, Haynes AC. Reduction of Cysteine Sulfinic Acid in Eukaryotic, Typical 2-Cys Peroxiredoxins by Sulfiredoxin. Antioxid Redox Signal 2011;15:99–109.
   PubMed Web of Science ®Google Scholar
• Findlay VJ, Tapiero H, Townsend DM. Sulfiredoxin: a potential therapeutic agent? Biomed Pharmacother 2005;59:374–379.
   PubMed Web of Science ®Google Scholar
• Rhee SG, Jeong W, Chang TS, Woo HA. Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance. Kidney Int Suppl 2007:S3–S8.
   Google Scholar
• Findlay VJ, Townsend DM, Morris TE, Fraser JP, He L, Tew KD. A novel role for human sulfiredoxin in the reversal of glutathionylation. Cancer Res 2006;66:6800–6806.
   PubMed Web of Science ®Google Scholar
• Kim Y, Chay KO, Kim I, Song YB, Kim TY, Han SJ, Ahn Y, Cho SH, Hoe KL, Ahn BW, Huh WK, Lee SR. Redox regulation of the tumor suppressor PTEN by glutaredoxin 5 and Ycp4. Biochem Biophys Res Commun 2011; 407:175–180.
   Google Scholar